Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 3/2012

01.03.2012 | Original Paper

Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients

verfasst von: Gregory Lucien Bellot, Wei Han Tan, Ling Lee Tay, Dean Koh, Xueying Wang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Since primary tumor cells from patients have been used as a model for assessment of drug response for individual patients, this study aims to evaluate the reliability of such a model in colorectal cancer (CRC) in predicting the response of tumor tissues through comparison of their expression profiles.

Methods

Establishment of primary cultures from tissues obtained surgically from CRC patients allowed us to study the gene expression differences between normal and tumor tissues as well as primary cultures derived from the tumor mass. The tissues comparison highlights the molecular characteristics of tumors, while the comparison between primary tumor cells versus normal and tumor tissues allowed us to identify alterations associated with the establishment of culture. Genes-drug association analyses allowed us to fine-tune our expectations while using primary culture as a model for drug assessment.

Results

Comparison between tumor cultures and original tissues through functional analyses showed the deregulations caused by culture establishment. Investigating the impact of such changes in genes-drug associations to identify the potential alterations in drug response, we found that primary cultures may have increased susceptibility toward paclitaxel, but reduced susceptibility toward analogues of fluorouracil compared with original tumors.

Conclusions

Response of primary tumor cells toward different drugs is not linearly associated to tumor tissues. Our results highlight the importance to account for the discrepancy in responses between the primary tumor cells and original counterparts in order to provide clinicians with important insights to improve selection of drugs for individual patients based on in vitro assays.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Alberts DS, Samon SE, Chen HS, Surwit EA, Soehnlen B, Young L et al (1980) In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2(8190):340–342PubMedCrossRef Alberts DS, Samon SE, Chen HS, Surwit EA, Soehnlen B, Young L et al (1980) In vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet 2(8190):340–342PubMedCrossRef
Zurück zum Zitat Arango D, Wilson A, Shi Q, Corner G, Arañes M, Nicholas C et al (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91(11):1931–1946PubMedCrossRef Arango D, Wilson A, Shi Q, Corner G, Arañes M, Nicholas C et al (2004) Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91(11):1931–1946PubMedCrossRef
Zurück zum Zitat Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R et al (2005) Gene-expression profiling predicts recurrence in Dukes’ C colorectal cancer. Gastroenterology 129(3):874–884PubMedCrossRef Arango D, Laiho P, Kokko A, Alhopuro P, Sammalkorpi H, Salovaara R et al (2005) Gene-expression profiling predicts recurrence in Dukes’ C colorectal cancer. Gastroenterology 129(3):874–884PubMedCrossRef
Zurück zum Zitat Bainard L, Bainard J, Newmaster S, Klironomos J (2011) Mycorrhizal symbiosis stimulates endoreduplication in angiosperms. Plant Cell Environ 34(9):1577–1585PubMedCrossRef Bainard L, Bainard J, Newmaster S, Klironomos J (2011) Mycorrhizal symbiosis stimulates endoreduplication in angiosperms. Plant Cell Environ 34(9):1577–1585PubMedCrossRef
Zurück zum Zitat Barrier A, Lemoine A, Boelle P, Tse C, Brault D, Chiappini F et al (2005a) Colon cancer prognosis prediction by gene expression profiling. Oncogene 24(40):6155–6164PubMedCrossRef Barrier A, Lemoine A, Boelle P, Tse C, Brault D, Chiappini F et al (2005a) Colon cancer prognosis prediction by gene expression profiling. Oncogene 24(40):6155–6164PubMedCrossRef
Zurück zum Zitat Barrier A, Boelle PY, Lemoine A, Tse C, Brault D, Chiappini F et al (2005b) Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 48(12):2238–2248PubMedCrossRef Barrier A, Boelle PY, Lemoine A, Tse C, Brault D, Chiappini F et al (2005b) Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 48(12):2238–2248PubMedCrossRef
Zurück zum Zitat Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24(29):4685–4691PubMedCrossRef Barrier A, Boelle PY, Roser F, Gregg J, Tse C, Brault D et al (2006) Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 24(29):4685–4691PubMedCrossRef
Zurück zum Zitat Barrier A, Roser F, Boëlle PY, Franc B, Tse C, Brault D et al (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26(18):2642–2648PubMedCrossRef Barrier A, Roser F, Boëlle PY, Franc B, Tse C, Brault D et al (2007) Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Oncogene 26(18):2642–2648PubMedCrossRef
Zurück zum Zitat Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238–1242PubMedCrossRef Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238–1242PubMedCrossRef
Zurück zum Zitat Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA et al (2005) Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study. Ann Oncol 16(Suppl 4):iv50–iv55PubMedCrossRef Bazan V, Agnese V, Corsale S, Calò V, Valerio MR, Latteri MA et al (2005) Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study. Ann Oncol 16(Suppl 4):iv50–iv55PubMedCrossRef
Zurück zum Zitat Brouquet A, Taleb P, Lot AS, Beauchet A, Julie C, Prevost G et al (2011) A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity. J Surg Res 166(2):247–254PubMedCrossRef Brouquet A, Taleb P, Lot AS, Beauchet A, Julie C, Prevost G et al (2011) A model of primary culture of colorectal cancer and liver metastasis to predict chemosensitivity. J Surg Res 166(2):247–254PubMedCrossRef
Zurück zum Zitat Cardoso J, Boer J, Morreau H, Fodde R (2007) Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 1775(1):103–137PubMed Cardoso J, Boer J, Morreau H, Fodde R (2007) Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 1775(1):103–137PubMed
Zurück zum Zitat Chen J, Aronow B, Jegga A (2009a) Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics 10:73PubMedCrossRef Chen J, Aronow B, Jegga A (2009a) Disease candidate gene identification and prioritization using protein interaction networks. BMC Bioinformatics 10:73PubMedCrossRef
Zurück zum Zitat Chen J, Bardes EE, Aronow BJ, Jegga AG (2009b) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37(Web Server issue):W305–W311PubMedCrossRef Chen J, Bardes EE, Aronow BJ, Jegga AG (2009b) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37(Web Server issue):W305–W311PubMedCrossRef
Zurück zum Zitat Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25(6):534–555PubMedCrossRef Chin L, Hahn WC, Getz G, Meyerson M (2011) Making sense of cancer genomic data. Genes Dev 25(6):534–555PubMedCrossRef
Zurück zum Zitat Collins FS, Green ED, Guttmacher AE, US National Human Genome Research Institute (2003) A vision for the future of genomics research. Nature 422(6934):835–847PubMedCrossRef Collins FS, Green ED, Guttmacher AE, US National Human Genome Research Institute (2003) A vision for the future of genomics research. Nature 422(6934):835–847PubMedCrossRef
Zurück zum Zitat Cree IA, Glaysher S, Harvey AL (2010) Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10(4):375–379PubMedCrossRef Cree IA, Glaysher S, Harvey AL (2010) Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue. Curr Opin Pharmacol 10(4):375–379PubMedCrossRef
Zurück zum Zitat Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, Rosenstein M et al (2011) The comparative toxicogenomics database: update 2011. Nucleic Acids Res 39(Database issue):D1067–D1072PubMedCrossRef Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, Rosenstein M et al (2011) The comparative toxicogenomics database: update 2011. Nucleic Acids Res 39(Database issue):D1067–D1072PubMedCrossRef
Zurück zum Zitat Del R, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P et al (2007) Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 25(7):773–780CrossRef Del R, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P et al (2007) Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol 25(7):773–780CrossRef
Zurück zum Zitat Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A et al (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23(15):3526–3535PubMedCrossRef Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A et al (2005) Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 23(15):3526–3535PubMedCrossRef
Zurück zum Zitat Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA et al (2006) Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anticancer Drugs 17(8):913–919PubMedCrossRef Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA et al (2006) Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anticancer Drugs 17(8):913–919PubMedCrossRef
Zurück zum Zitat Fruehauf J, Alberts D (2003) Assay-assisted treatment selection for women with breast or ovarian cancer. Recent Results Cancer Res 161:126–145PubMedCrossRef Fruehauf J, Alberts D (2003) Assay-assisted treatment selection for women with breast or ovarian cancer. Recent Results Cancer Res 161:126–145PubMedCrossRef
Zurück zum Zitat Fruehauf JP, Alberts DS (2005) In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 23(15):3641–3643 author reply 3646PubMedCrossRef Fruehauf JP, Alberts DS (2005) In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 23(15):3641–3643 author reply 3646PubMedCrossRef
Zurück zum Zitat Fu Z, Tindall DJ (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27(16):2312–2319PubMedCrossRef Fu Z, Tindall DJ (2008) FOXOs, cancer and regulation of apoptosis. Oncogene 27(16):2312–2319PubMedCrossRef
Zurück zum Zitat Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47–76PubMedCrossRef Gillet JP, Gottesman MM (2010) Mechanisms of multidrug resistance in cancer. Methods Mol Biol 596:47–76PubMedCrossRef
Zurück zum Zitat Jeppesen P (2000) Immunofluorescence in cytogenetic analysis: method and applications. Genet Mol Bio 23:1003–1014CrossRef Jeppesen P (2000) Immunofluorescence in cytogenetic analysis: method and applications. Genet Mol Bio 23:1003–1014CrossRef
Zurück zum Zitat Khambata-Ford S, Garrett C, Meropol N, Basik M, Harbison C, Wu S et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230–3237PubMedCrossRef Khambata-Ford S, Garrett C, Meropol N, Basik M, Harbison C, Wu S et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230–3237PubMedCrossRef
Zurück zum Zitat Kulendran M, Stebbing JF, Marks CG, Rockall TA (2011) Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers 3(2):1622–1638CrossRef Kulendran M, Stebbing JF, Marks CG, Rockall TA (2011) Predictive and prognostic factors in colorectal cancer: a personalized approach. Cancers 3(2):1622–1638CrossRef
Zurück zum Zitat La Farina M, Maturi N, Stira S, Russo A, Bazan V, Albanese I et al (1998) Direct identification of each specific mutation in codon 12 and 13 of ci-ki-ras2 by SSCP analysis. Biochem Biophys Res Commun 246(3):813–815PubMedCrossRef La Farina M, Maturi N, Stira S, Russo A, Bazan V, Albanese I et al (1998) Direct identification of each specific mutation in codon 12 and 13 of ci-ki-ras2 by SSCP analysis. Biochem Biophys Res Commun 246(3):813–815PubMedCrossRef
Zurück zum Zitat Lee J, Lee I, Han B, Park J, Jang J, Park C et al (2011) Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103(8):674–688PubMedCrossRef Lee J, Lee I, Han B, Park J, Jang J, Park C et al (2011) Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 103(8):674–688PubMedCrossRef
Zurück zum Zitat Lippert TH, Ruoff HJ, Volm M (2011) Current status of methods to assess cancer drug resistance. Int J Med Sci 8(3):245–253PubMedCrossRef Lippert TH, Ruoff HJ, Volm M (2011) Current status of methods to assess cancer drug resistance. Int J Med Sci 8(3):245–253PubMedCrossRef
Zurück zum Zitat Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML et al (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189(5):1301–1307PubMedCrossRef Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML et al (2003) Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189(5):1301–1307PubMedCrossRef
Zurück zum Zitat Luca T, Privitera G, Lo Monaco M, Prezzavento C, Castorina S (2007) Validation study of a cell culture model of colorectal cancer. Ital J Anat Embryol 112(2):81–92PubMed Luca T, Privitera G, Lo Monaco M, Prezzavento C, Castorina S (2007) Validation study of a cell culture model of colorectal cancer. Ital J Anat Embryol 112(2):81–92PubMed
Zurück zum Zitat Mariadason J, Arango D, Shi Q, Wilson A, Corner G, Nicholas C et al (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63(24):8791–8812PubMed Mariadason J, Arango D, Shi Q, Wilson A, Corner G, Nicholas C et al (2003) Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res 63(24):8791–8812PubMed
Zurück zum Zitat Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P et al (2010) Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol 2010:861341PubMed Marrinucci D, Bethel K, Lazar D, Fisher J, Huynh E, Clark P et al (2010) Cytomorphology of circulating colorectal tumor cells:a small case series. J Oncol 2010:861341PubMed
Zurück zum Zitat Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K et al (1990) Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res 50(22):7166–7173PubMed Miyaki M, Seki M, Okamoto M, Yamanaka A, Maeda Y, Tanaka K et al (1990) Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res 50(22):7166–7173PubMed
Zurück zum Zitat Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M (1995) Familial polyposis: recent advances. Crit Rev Oncol Hematol 19(1):1–31PubMedCrossRef Miyaki M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Konishi M (1995) Familial polyposis: recent advances. Crit Rev Oncol Hematol 19(1):1–31PubMedCrossRef
Zurück zum Zitat Moyer A, Sun Z, Batzler A, Li L, Schaid D, Yang P et al (2010) Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 19(3):811–821PubMedCrossRef Moyer A, Sun Z, Batzler A, Li L, Schaid D, Yang P et al (2010) Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol Biomarkers Prev 19(3):811–821PubMedCrossRef
Zurück zum Zitat Muleris M, Salmon R, Dutrillaux B (1990) Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet 46(2):143–156PubMedCrossRef Muleris M, Salmon R, Dutrillaux B (1990) Cytogenetics of colorectal adenocarcinomas. Cancer Genet Cytogenet 46(2):143–156PubMedCrossRef
Zurück zum Zitat Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446(7137):758–764PubMedCrossRef Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al (2007) Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 446(7137):758–764PubMedCrossRef
Zurück zum Zitat Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191):110–114PubMedCrossRef Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al (2008) BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 453(7191):110–114PubMedCrossRef
Zurück zum Zitat Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G et al (2009) Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 35(3):201–209PubMedCrossRef Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G et al (2009) Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 35(3):201–209PubMedCrossRef
Zurück zum Zitat Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y et al (2008) Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 61(4):587–594PubMedCrossRef Okumura K, Mekata E, Shiomi H, Naitoh H, Abe H, Endo Y et al (2008) Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer. Cancer Chemother Pharmacol 61(4):587–594PubMedCrossRef
Zurück zum Zitat Penland SK, Goldberg RM (2004) Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park) 18(6):715–722 727, discussion 727 Penland SK, Goldberg RM (2004) Current strategies in previously untreated advanced colorectal cancer. Oncology (Williston Park) 18(6):715–722 727, discussion 727
Zurück zum Zitat Pezo R, Gandhi S, Shirley L, Pestell R, Augenlicht L, Singer R et al (2008) Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. Cancer Res 68(13):4977–4982PubMedCrossRef Pezo R, Gandhi S, Shirley L, Pestell R, Augenlicht L, Singer R et al (2008) Single-cell transcription site activation predicts chemotherapy response in human colorectal tumors. Cancer Res 68(13):4977–4982PubMedCrossRef
Zurück zum Zitat Puig P, Guilly M, Bouchot A, Droin N, Cathelin D, Bouyer F et al (2008) Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 32(9):1031–1043PubMedCrossRef Puig P, Guilly M, Bouchot A, Droin N, Cathelin D, Bouyer F et al (2008) Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int 32(9):1031–1043PubMedCrossRef
Zurück zum Zitat Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34(2):374–378PubMed Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N et al (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34(2):374–378PubMed
Zurück zum Zitat Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR et al (2004) American society of clinical oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22(17):3631–3638PubMedCrossRef Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR et al (2004) American society of clinical oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22(17):3631–3638PubMedCrossRef
Zurück zum Zitat Schwerer MJ, Hemmer J, Kraft K, Maier H, Möller P, Barth TFE et al (2003) Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma. Virchows Arch 443(1):98–103PubMedCrossRef Schwerer MJ, Hemmer J, Kraft K, Maier H, Möller P, Barth TFE et al (2003) Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma. Virchows Arch 443(1):98–103PubMedCrossRef
Zurück zum Zitat Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y et al (2005) Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol 27(2):371–376PubMed Shimizu D, Ishikawa T, Ichikawa Y, Togo S, Hayasizaki Y, Okazaki Y et al (2005) Prediction of chemosensitivity of colorectal cancer to 5-fluorouracil by gene expression profiling with cDNA microarrays. Int J Oncol 27(2):371–376PubMed
Zurück zum Zitat Stein WD, Litman T, Fojo T, Bates SE (2004) A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 64(8):2805–2816PubMedCrossRef Stein WD, Litman T, Fojo T, Bates SE (2004) A serial analysis of gene expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. Cancer Res 64(8):2805–2816PubMedCrossRef
Zurück zum Zitat Szakács G, Gottesman MM (2004) Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. Mol Interv 4(6):323–325PubMedCrossRef Szakács G, Gottesman MM (2004) Comparing solid tumors with cell lines: implications for identifying drug resistance genes in cancer. Mol Interv 4(6):323–325PubMedCrossRef
Zurück zum Zitat Varesco L, Gismondi V, James R, Robertson M, Grammatico P, Groden J et al (1993) Identification of APC gene mutations in Italian adenomatous polyposis coli patients by PCR-SSCP analysis. Am J Hum Genet 52(2):280–285PubMed Varesco L, Gismondi V, James R, Robertson M, Grammatico P, Groden J et al (1993) Identification of APC gene mutations in Italian adenomatous polyposis coli patients by PCR-SSCP analysis. Am J Hum Genet 52(2):280–285PubMed
Zurück zum Zitat Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893–898PubMedCrossRef Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450(7171):893–898PubMedCrossRef
Zurück zum Zitat Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW et al (2005) Colorectal cancer. Lancet 365(9454):153–165PubMedCrossRef Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW et al (2005) Colorectal cancer. Lancet 365(9454):153–165PubMedCrossRef
Zurück zum Zitat Williams B, Bateman J, Novikov N, Wu C (2007) Disruption of topoisomerase II perturbs pairing in drosophila cell culture. Genetics 177(1):31–46PubMedCrossRef Williams B, Bateman J, Novikov N, Wu C (2007) Disruption of topoisomerase II perturbs pairing in drosophila cell culture. Genetics 177(1):31–46PubMedCrossRef
Zurück zum Zitat Wilson M, Brosens J, Schwenen H, Lam E (2011) FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets 12(9):1256–1266PubMedCrossRef Wilson M, Brosens J, Schwenen H, Lam E (2011) FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets 12(9):1256–1266PubMedCrossRef
Metadaten
Titel
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients
verfasst von
Gregory Lucien Bellot
Wei Han Tan
Ling Lee Tay
Dean Koh
Xueying Wang
Publikationsdatum
01.03.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 3/2012
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-011-1115-9

Weitere Artikel der Ausgabe 3/2012

Journal of Cancer Research and Clinical Oncology 3/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.